Scholarlink

Background <p>The respiratory rate–oxygenation (ROX) index (calculated as [SpO₂/FiO₂ ratio] / respiratory rate) is reported to be associated with outcomes in patients with acute hypoxemic respiratory failure treated with a high-flow nasal cannula (HFNC). However, its prognostic utility in acute exacerbation of interstitial lung disease (AE-ILD) remains unclear.</p> Methods <p>We conducted a single-center retrospective cohort study that included patients with AE-ILD who received HFNC between April 2016 and June 2023. The ROX index at HFNC initiation (0&#xa0;h) and 12&#xa0;h was recorded. The primary outcome was 30-day mortality. Logistic regression analysis was also performed.</p> Results <p>In total, 92 patients were included in this study; their median age was 80 years, and 73% were male. Univariate analysis revealed that 30-day mortality was associated with the ROX index at 0&#xa0;h (odds ratio [OR], 0.80; 95% confidence interval [CI]: 0.63–1.00; <i>p</i> = 0.048) and 12&#xa0;h (OR, 0.66; 95% CI: 0.50–0.85; <i>p</i> = 0.001). Multivariate analysis revealed that the ROX index at 12&#xa0;h was independently associated with 30-day mortality (OR, 0.67; 95% CI: 0.51–0.88; <i>p</i> = 0.003). The optimal cutoff value of the ROX index at 12&#xa0;h for 30-day mortality was 5.82 (area under the curve: 0.76).</p> Conclusions <p>The ROX index at 12&#xa0;h after HFNC was associated with 30-day mortality in patients with AE-ILD and may serve as a simple bedside marker for short-term prognosis.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prognostic significance of the ROX index in patients with acute exacerbation of interstitial lung disease treated with high-flow nasal cannula oxygen therapy: a retrospective cohort study

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年4月30日

查看全文
  • Issei Katayama,
  • Hideki Makino,
  • Saki Sahara,
  • Yuki Kayada,
  • Kazuki Oshita,
  • So Ueda,
  • Takuyuki Koda,
  • Kotaro Kajiwara,
  • Takanori Kanematsu

摘要

Background

The respiratory rate–oxygenation (ROX) index (calculated as [SpO₂/FiO₂ ratio] / respiratory rate) is reported to be associated with outcomes in patients with acute hypoxemic respiratory failure treated with a high-flow nasal cannula (HFNC). However, its prognostic utility in acute exacerbation of interstitial lung disease (AE-ILD) remains unclear.

Methods

We conducted a single-center retrospective cohort study that included patients with AE-ILD who received HFNC between April 2016 and June 2023. The ROX index at HFNC initiation (0 h) and 12 h was recorded. The primary outcome was 30-day mortality. Logistic regression analysis was also performed.

Results

In total, 92 patients were included in this study; their median age was 80 years, and 73% were male. Univariate analysis revealed that 30-day mortality was associated with the ROX index at 0 h (odds ratio [OR], 0.80; 95% confidence interval [CI]: 0.63–1.00; p = 0.048) and 12 h (OR, 0.66; 95% CI: 0.50–0.85; p = 0.001). Multivariate analysis revealed that the ROX index at 12 h was independently associated with 30-day mortality (OR, 0.67; 95% CI: 0.51–0.88; p = 0.003). The optimal cutoff value of the ROX index at 12 h for 30-day mortality was 5.82 (area under the curve: 0.76).

Conclusions

The ROX index at 12 h after HFNC was associated with 30-day mortality in patients with AE-ILD and may serve as a simple bedside marker for short-term prognosis.